Actinium Pharmaceuticals, Inc. (ATNM)

1.780.01 (-0.56%)

Actinium Pharmaceuticals, Inc. (ATNM) stock comprehensive Financial Growth Analysis including revenue, gross profit, operating profit, net profit, EPS, and other financial metrics. Compare financial growth against peers/competitors, industry and sector standards.

High Bankruptcy RiskBelow Average ESGFair ValuationLow ProfitabilityAdequate Financial HealthInefficient OperationsModerate GrowthLow QualityAdequate Dividend ProfileIndustry Rank: 20.71%Sector Rank: 20.19%

AMEX - Healthcare - Biotechnology | Market Cap: 55.53M | Next Earnings Date: 13 Nov 2025

Day's Range

1.75 - 1.81

52-Week Range

1.03 - 2.41

Volume

122.5K / 296.7K (Avg.)

P/E Ratio | EPS

-1.36 | -1.31

Trending:

ATNM Financial Growth Analysis - Compare Against TRAW

Comparison against TRAW

None AGEN AVXL RVPH AXSM TRAW

Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.

Revenue Growth

No Data

No Data available this quarter, please select a different quarter.

Gross Profit Growth

No Data

No Data available this quarter, please select a different quarter.

EBIT Growth

-116.92%

Decreased from previous period

Negative EBIT growth while TRAW is at 196.33%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.

Operating Income Growth

-185.87%

Increased from previous period

Negative operating income growth while TRAW is at 184.55%. Joel Greenblatt would press for urgent turnaround measures.

Net Income Growth

-92.79%

Increased from previous period

Negative net income growth while TRAW stands at 80.65%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.

EPS Growth

-3998.91%

Increased from previous period

Negative EPS growth while TRAW is at 80.65%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.

Diluted EPS Growth

-3998.91%

Increased from previous period

Negative diluted EPS growth while TRAW is at 80.65%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.

Share Count Growth (Basic)

-95.29%

Decreased from previous period

Share reduction while TRAW is at 0.00%. Joel Greenblatt would see if the company has a better buyback policy than the competitor.

Share Count Growth (Diluted)

-95.29%

Decreased from previous period

Reduced diluted shares while TRAW is at 0.00%. Joel Greenblatt would see a relative advantage if the competitor is diluting more.

Dividend per Share Growth

No Data

No Data available this quarter, please select a different quarter.

Operating Cash Flow Growth

75.47%

Increased from previous period

OCF growth under 50% of TRAW's 775.45%. Michael Burry might suspect questionable revenue recognition or rising costs.

Free Cash Flow Growth

66.24%

Increased from previous period

FCF growth under 50% of TRAW's 773.20%. Michael Burry would suspect weaker operating efficiencies or heavier capex burdens.

10-Year Revenue Growth per Share (CAGR)

No Data

No Data available this quarter, please select a different quarter.

5-Year Revenue Growth per Share (CAGR)

No Data

No Data available this quarter, please select a different quarter.

3-Year Revenue Growth per Share (CAGR)

No Data

No Data available this quarter, please select a different quarter.

10-Year Operating Cash Flow Growth per Share

-141.36%

Decreased from previous period

Negative 10Y OCF/share CAGR while TRAW stands at 0.00%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.

5-Year Operating Cash Flow Growth per Share

-420.27%

Decreased from previous period

Negative 5Y OCF/share CAGR while TRAW is at 0.00%. Joel Greenblatt would question the firm’s operational model or cost structure.

3-Year Operating Cash Flow Growth per Share

-362.87%

Increased from previous period

Negative 3Y OCF/share CAGR while TRAW stands at 0.00%. Joel Greenblatt would demand an urgent turnaround in the firm’s cost or revenue drivers.

10-Year Net Income Growth per Share

-427041.90%

Decreased from previous period

Negative 10Y net income/share CAGR while TRAW is at 0.00%. Joel Greenblatt sees a major red flag in long-term profit erosion.

5-Year Net Income Growth per Share

-659606.65%

Decreased from previous period

Negative 5Y net income/share CAGR while TRAW is 0.00%. Joel Greenblatt would see fundamental missteps limiting profitability vs. the competitor.

3-Year Net Income Growth per Share

-1088784.48%

Decreased from previous period

Negative 3Y CAGR while TRAW is 0.00%. Joel Greenblatt might call for a short-term turnaround strategy or cost realignment.

10-Year Shareholders’ Equity Growth per Share

No Data

No Data available this quarter, please select a different quarter.

5-Year Shareholders’ Equity Growth per Share

-4964.64%

Decreased from previous period

Negative 5Y equity/share growth while TRAW is at 0.00%. Joel Greenblatt sees the competitor building net worth while this firm loses ground.

3-Year Shareholders’ Equity Growth per Share

-1566.95%

Decreased from previous period

Negative 3Y equity/share growth while TRAW is at 0.00%. Joel Greenblatt demands an urgent fix in capital structure or profitability vs. the competitor.

10-Year Dividend per Share Growth (CAGR)

No Data

No Data available this quarter, please select a different quarter.

5-Year Dividend per Share Growth (CAGR)

No Data

No Data available this quarter, please select a different quarter.

3-Year Dividend per Share Growth (CAGR)

No Data

No Data available this quarter, please select a different quarter.

Receivables Growth

No Data

No Data available this quarter, please select a different quarter.

Inventory Growth

No Data

No Data available this quarter, please select a different quarter.

Asset Growth

1993307.75%

Increased from previous period

Asset growth of 1993307.75% while TRAW is zero. Bruce Berkowitz checks if modest expansions can create a longer-term lead.

Book Value per Share Growth

57821.37%

Increased from previous period

BV/share growth of 57821.37% while TRAW is zero. Bruce Berkowitz sees if small growth can compound into a strong advantage.

Debt Growth

2.24%

Decreased from previous period

Debt growth of 2.24% while TRAW is zero. Bruce Berkowitz sees additional leverage that must yield profitable expansions to be worthwhile.

R&D Expense Growth

178.96%

Increased from previous period

R&D growth drastically higher vs. TRAW's 297.90%. Michael Burry fears near-term margin erosion unless breakthroughs are imminent.

SG&A Expenses Growth

203.49%

Decreased from previous period

SG&A declining or stable vs. TRAW's 448.37%. David Dodd sees better overhead efficiency if it doesn't hamper revenue.

+ Add New Metric (Coming Soon)

Add more metric or remove existing ones, customize as per your preference, feature coming soon!

Select Chart Metric:

ATNM Financial Growth Analysis - Compare Against TRAW

Comparison against TRAW

None AGEN AVXL RVPH AXSM TRAW

Revenue Growth

No Data

No Data available this quarter, please select a different quarter.

Gross Profit Growth

No Data

No Data available this quarter, please select a different quarter.

EBIT Growth

-116.92%

Decreased from previous period

Negative EBIT growth while TRAW is at 196.33%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.

Operating Income Growth

-185.87%

Increased from previous period

Negative operating income growth while TRAW is at 184.55%. Joel Greenblatt would press for urgent turnaround measures.

Net Income Growth

-92.79%

Increased from previous period

Negative net income growth while TRAW stands at 80.65%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.

EPS Growth

-3998.91%

Increased from previous period

Negative EPS growth while TRAW is at 80.65%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.

Diluted EPS Growth

-3998.91%

Increased from previous period

Negative diluted EPS growth while TRAW is at 80.65%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.

Share Count Growth (Basic)

-95.29%

Decreased from previous period

Share reduction while TRAW is at 0.00%. Joel Greenblatt would see if the company has a better buyback policy than the competitor.

Share Count Growth (Diluted)

-95.29%

Decreased from previous period

Reduced diluted shares while TRAW is at 0.00%. Joel Greenblatt would see a relative advantage if the competitor is diluting more.

Dividend per Share Growth

No Data

No Data available this quarter, please select a different quarter.

Operating Cash Flow Growth

75.47%

Increased from previous period

OCF growth under 50% of TRAW's 775.45%. Michael Burry might suspect questionable revenue recognition or rising costs.

Free Cash Flow Growth

66.24%

Increased from previous period

FCF growth under 50% of TRAW's 773.20%. Michael Burry would suspect weaker operating efficiencies or heavier capex burdens.

10-Year Revenue Growth per Share (CAGR)

No Data

No Data available this quarter, please select a different quarter.

5-Year Revenue Growth per Share (CAGR)

No Data

No Data available this quarter, please select a different quarter.

3-Year Revenue Growth per Share (CAGR)

No Data

No Data available this quarter, please select a different quarter.

10-Year Operating Cash Flow Growth per Share

-141.36%

Decreased from previous period

Negative 10Y OCF/share CAGR while TRAW stands at 0.00%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.

5-Year Operating Cash Flow Growth per Share

-420.27%

Decreased from previous period

Negative 5Y OCF/share CAGR while TRAW is at 0.00%. Joel Greenblatt would question the firm’s operational model or cost structure.

3-Year Operating Cash Flow Growth per Share

-362.87%

Increased from previous period

Negative 3Y OCF/share CAGR while TRAW stands at 0.00%. Joel Greenblatt would demand an urgent turnaround in the firm’s cost or revenue drivers.

10-Year Net Income Growth per Share

-427041.90%

Decreased from previous period

Negative 10Y net income/share CAGR while TRAW is at 0.00%. Joel Greenblatt sees a major red flag in long-term profit erosion.

5-Year Net Income Growth per Share

-659606.65%

Decreased from previous period

Negative 5Y net income/share CAGR while TRAW is 0.00%. Joel Greenblatt would see fundamental missteps limiting profitability vs. the competitor.

3-Year Net Income Growth per Share

-1088784.48%

Decreased from previous period

Negative 3Y CAGR while TRAW is 0.00%. Joel Greenblatt might call for a short-term turnaround strategy or cost realignment.

10-Year Shareholders’ Equity Growth per Share

No Data

No Data available this quarter, please select a different quarter.

5-Year Shareholders’ Equity Growth per Share

-4964.64%

Decreased from previous period

Negative 5Y equity/share growth while TRAW is at 0.00%. Joel Greenblatt sees the competitor building net worth while this firm loses ground.

3-Year Shareholders’ Equity Growth per Share

-1566.95%

Decreased from previous period

Negative 3Y equity/share growth while TRAW is at 0.00%. Joel Greenblatt demands an urgent fix in capital structure or profitability vs. the competitor.

10-Year Dividend per Share Growth (CAGR)

No Data

No Data available this quarter, please select a different quarter.

5-Year Dividend per Share Growth (CAGR)

No Data

No Data available this quarter, please select a different quarter.

3-Year Dividend per Share Growth (CAGR)

No Data

No Data available this quarter, please select a different quarter.

Receivables Growth

No Data

No Data available this quarter, please select a different quarter.

Inventory Growth

No Data

No Data available this quarter, please select a different quarter.

Asset Growth

1993307.75%

Increased from previous period

Asset growth of 1993307.75% while TRAW is zero. Bruce Berkowitz checks if modest expansions can create a longer-term lead.

Book Value per Share Growth

57821.37%

Increased from previous period

BV/share growth of 57821.37% while TRAW is zero. Bruce Berkowitz sees if small growth can compound into a strong advantage.

Debt Growth

2.24%

Decreased from previous period

Debt growth of 2.24% while TRAW is zero. Bruce Berkowitz sees additional leverage that must yield profitable expansions to be worthwhile.

R&D Expense Growth

178.96%

Increased from previous period

R&D growth drastically higher vs. TRAW's 297.90%. Michael Burry fears near-term margin erosion unless breakthroughs are imminent.

SG&A Expenses Growth

203.49%

Decreased from previous period

SG&A declining or stable vs. TRAW's 448.37%. David Dodd sees better overhead efficiency if it doesn't hamper revenue.

+ Add New Metric (Coming Soon)

Add more metric or remove existing ones, customize as per your preference, feature coming soon!

Select Chart Metric: